Georgoulas Stelios, Dahlmann-Noor Annegret, Brocchini Stephen, Khaw Peng Tee
Ocular Repair and Regeneration Biology Research Unit, National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust, London EC1V 9EL, UK.
Prog Brain Res. 2008;173:237-54. doi: 10.1016/S0079-6123(08)01117-5.
Following all types of glaucoma filtration surgery (GFS), scarring still poses the major threat to long-term success. The healing and scarring determine the percentage of patients achieving low final intraocular pressures (IOPs) that are associated with virtually no glaucoma progression. The use of antifibrotic agents to inhibit scarring of trabeculectomy blebs is now a well-established clinical practice. Unfortunately, severe complications such as leakage, infection, hypotony, and endophthalmitis with complete loss of vision may occur. In addition, surgery still fails in some individuals despite maximal doses of current antifibrotics. Better therapeutic agents are needed. Many promising new agents are being evaluated clinically and in vitro. In this chapter, we will discuss our current understanding of the wound healing process after glaucoma surgery and promising new treatment modalities.
在所有类型的青光眼滤过手术（GFS）之后，瘢痕形成仍然是长期成功的主要威胁。愈合和瘢痕形成决定了眼压最终降低到几乎不会导致青光眼进展的患者比例。使用抗纤维化药物抑制小梁切除术滤过泡的瘢痕形成现在是一种成熟的临床实践。不幸的是，可能会发生严重并发症，如渗漏、感染、低眼压和全眼球炎并导致视力完全丧失。此外，尽管使用了当前抗纤维化药物的最大剂量，手术在一些个体中仍然失败。需要更好的治疗药物。许多有前景的新药物正在进行临床和体外评估。在本章中，我们将讨论目前对青光眼手术后伤口愈合过程的理解以及有前景的新治疗方式。
